Skip to main content
main-content

Tipp

Weitere Kapitel dieses Buchs durch Wischen aufrufen

2020 | OriginalPaper | Buchkapitel

14. Nanomaterials and Ethical Issues

verfasst von : Oodhimalai Elango Santhini, Selvaraj Dinesh Kirupha

Erschienen in: Applications of Nanomaterials in Human Health

Verlag: Springer Singapore

share
TEILEN

Abstract

Even after many discoveries and inventions of new nanomaterial devices for biomedical applications, still there were no stringent rules and regulations framed for the pharmaceutical products or the biomedicines developed from it. As a result, there was a bridge gap between biomedical advancement and clinical trials. This chapter discusses about the nanomaterial’s advancement, importance and its key role in the development of novel and improvised biomedical devices for many health-related issues in human body. There was a sharp edge of advancement with many novel inventions, at the same time there was a lack in discipline in the ethical issues and advancement related to it. Hence this chapter clearly connects the bridge between the issues and presented some improvisations for the development of nanobiomedical devices and their ethical issues.
Literatur
Zurück zum Zitat Arts JHE, Hadi M, Irfan M, Keene AM, Kreiling R, Lyon D, Maier M, Michel K, Petry T, Sauer UG, Wiench K, Wohlleben W, Landsiedel R, Warheit D (2015) A decision-making framework for the grouping and testing of nanomaterials (DF4nanoGrouping). Regul Toxicol Pharm 71:S1–S27 CrossRef Arts JHE, Hadi M, Irfan M, Keene AM, Kreiling R, Lyon D, Maier M, Michel K, Petry T, Sauer UG, Wiench K, Wohlleben W, Landsiedel R, Warheit D (2015) A decision-making framework for the grouping and testing of nanomaterials (DF4nanoGrouping). Regul Toxicol Pharm 71:S1–S27 CrossRef
Zurück zum Zitat Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR (2016) Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date. Pharm Res. 33(10):2373–2387 CrossRef Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR (2016) Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date. Pharm Res. 33(10):2373–2387 CrossRef
Zurück zum Zitat Clichici S and Filip A (2015) Nanomaterials—toxicity and risk assessment. In In vivo assessment of nanomaterials toxicity. Licensee InTech. Clichici S and Filip A (2015) Nanomaterials—toxicity and risk assessment. In In vivo assessment of nanomaterials toxicity. Licensee InTech.
Zurück zum Zitat Food and Drug Administration (2017) Novel drug approvals for 2017. Oct 20. Food and Drug Administration (2017) Novel drug approvals for 2017. Oct 20.
Zurück zum Zitat Jones C, Grainger DW (2009) In vitro assessments of nanomaterial toxicity. Adv Drug Deliv Rev. 61(6):438–456 CrossRef Jones C, Grainger DW (2009) In vitro assessments of nanomaterial toxicity. Adv Drug Deliv Rev. 61(6):438–456 CrossRef
Zurück zum Zitat Kuzma J, Priest S (2010) Nanotechnology, risk and oversight: learning lessons from related emerging technologies. Risk Anal 30(11):1688–1698 CrossRef Kuzma J, Priest S (2010) Nanotechnology, risk and oversight: learning lessons from related emerging technologies. Risk Anal 30(11):1688–1698 CrossRef
Metadaten
Titel
Nanomaterials and Ethical Issues
verfasst von
Oodhimalai Elango Santhini
Selvaraj Dinesh Kirupha
Copyright-Jahr
2020
Verlag
Springer Singapore
DOI
https://doi.org/10.1007/978-981-15-4802-4_14

Premium Partner

    Marktübersichten

    Die im Laufe eines Jahres in der „adhäsion“ veröffentlichten Marktübersichten helfen Anwendern verschiedenster Branchen, sich einen gezielten Überblick über Lieferantenangebote zu verschaffen.